ENCell's EN001 Enters Phase 2a Trials for CMT1A
May 21, 2026
A South Korean biotech, ENCell, has dosed the first patient in a Phase 2a trial of EN001, a stem cell therapy aimed at the myelin damage behind CMT1A.
News & Stories
The latest from HNF: research updates, patient stories, advocacy wins, events, and CMT community news.
No matches for .
Showing 1 to 12 of 314
-
-
HNF to Host FDA Patient Listening Session for CMT-SORD
May 21, 2026
HNF is hosting an FDA Patient Listening Session for the CMT-SORD community on August 4, giving patients and caregivers a direct line to the agency at a critical moment for the subtype.
-
Thank You for an Incredible 2026 CMT Clinical Trial Readiness Summit
May 21, 2026
Over 200 attendees made the 2026 CMT Summit our biggest gathering yet. Thank you to our sponsors, speakers, research participants, and every member of the community who came.
-
Your Genetic Report Could Help Unlock the Next CMT Breakthrough
May 21, 2026
If you have a genetic report related to your CMT diagnosis, uploading it to GRIN is one of the most direct contributions you can make to CMT research today. Even negative or inconclusive reports belong.
-
The 2026 CMT Summit: What We Built Together
May 18, 2026
-
MDA Durable Medical Equipment (DME) Grant Program
May 18, 2026
-
They Rode for a Cure and you Can Still Be Part of It
May 18, 2026
-
A New Program for Men Living with CMT
May 18, 2026
-
2026 Clinical Trial Readiness Summit
May 1, 2026
